Compass Pathways' depression treatment meets main goal in latestage study | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[Compass Pathways PLC]FollowFeb 17 (Reuters) - Drug developer Compass Pathways [(CMPS.O), opens new tab] said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.Sign up [here.]Reporting by Sahil Pandey in Bengaluru; Editing by Devika SyamnathOur Standards: [The ...

Core Insights - Teijin Pharma has entered a joint research agreement with Aska Pharmaceutical to develop small-molecule drug candidates targeting gynaecological diseases, leveraging Teijin's expertise in computer-aided drug design and AI [1][2] - The collaboration aims to identify "hit" compounds that interact with specific molecular targets, followed by optimization to ensure efficacy, pharmacokinetic properties, and safety for drug development [2][3] - Aska Pharmaceutical contributes clinical expertise in women's health, focusing on unmet medical needs, which complements Teijin's advanced drug discovery technologies [3][4] Company Strategies - Teijin Pharma is enhancing its drug candidate discovery process through improved simulation accuracy and predictive modeling, which shortens timelines and increases the probability of success in drug development [2] - Aska Pharmaceutical specializes in urology, internal medicine, and obstetrics and gynaecology, with a portfolio aimed at supporting women at various life stages [4] - The partnership aims to provide innovative treatments to improve the quality of life for women suffering from gynaecological conditions [4] Recent Developments - Teijin has submitted an application to Japan's Pharmaceuticals and Medical Devices Agency for manufacturing and marketing approval of lonapegsomatropin, a prodrug of somatropin, which is administered once weekly [5]

Core Insights - Duvakitug, an investigational human monoclonal antibody targeting TL1A, has shown durable clinical and endoscopic efficacy in patients with ulcerative colitis (UC) and Crohn's disease (CD) over a 44-week maintenance period following initial response in the induction phase [1][7] - The study results indicate that duvakitug has the potential to be a leading therapy for inflammatory bowel disease (IBD), with ongoing phase 3 studies to further evaluate its efficacy and safety [2][4] Study Details - The RELIEVE UCCD long-term extension study enrolled 130 patients who had responded to duvakitug in the induction study, with a maintenance period of 44 weeks where patients received either 450 mg or 900 mg doses every four weeks [2][12] - At week 44, 58% of patients on the 900 mg dose and 47% on the 450 mg dose achieved clinical remission in UC, while 55% on the 900 mg dose and 41% on the 450 mg dose achieved endoscopic response in CD [8] Safety and Tolerability - Both doses of duvakitug were well tolerated, with the most common adverse events being upper respiratory tract infection, nasopharyngitis, Crohn's disease, and hypertension, consistent with findings from the induction study [3][7] Industry Context - IBD is characterized by chronic inflammation of the gastrointestinal tract, with approximately 4.9 million cases globally, and the incidence is rising in several regions [5] - There is currently no cure for IBD, and treatment aims to induce and maintain remission while preventing flares [9]

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2 ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2 ...

Core Insights - Eli Lilly aims to establish India as a global export hub for its pharmaceutical products, leveraging a $1 billion investment in contract manufacturing [1] - The company's weight-loss drug Mounjaro has seen sales double shortly after its launch in India, becoming the top-selling medicine by value in the country [1] - Lilly plans to introduce additional products in India, including the Alzheimer's drug donanemab and potential future obesity treatments, pending regulatory approvals [1] Company Strategy - Eli Lilly does not currently have its own manufacturing facility in India but intends to export drugs produced locally to global markets [1] - The company is focused on enhancing digital and social media campaigns to raise awareness about obesity and expand Mounjaro's reach in smaller cities [1] - Partnerships with local firms, such as Cipla and digital health platforms like Tata 1MG, Practo, and Apollo, are part of Lilly's strategy to widen distribution [1] Market Competition - In India, Eli Lilly competes with Novo Nordisk, which produces Wegovy, as the market for weight-loss drugs is expected to grow significantly [1] - Novo Nordisk has reduced the price of Wegovy by up to 37% to maintain market share, but Lilly believes Mounjaro's superior efficacy will keep it competitive [1] - The expiration of Novo's patent on semaglutide is anticipated to lead to the launch of cheaper generic versions of Wegovy by local firms [1]

Core Viewpoint - BioNxt Solutions Inc. has received a Decision to Grant a European Patent for its proprietary sublingual cladribine oral thin film drug delivery technology, indicating a significant advancement in its product offerings and potential market position [1] Company Summary - BioNxt Solutions Inc. is a bioscience innovator focused on advanced drug delivery systems [1] - The company is publicly traded on multiple exchanges, including CSE, OTCQB, and FSE [1] Patent Information - The European Patent Office has granted European Patent No. 4539857 for BioNxt's sublingual cladribine oral thin film technology, which is a proprietary drug delivery method [1]

Group 1 - The Hong Kong stock market showed positive performance during the New Year holiday, with the Hang Seng Index rising by 0.52%, the Hang Seng China Enterprises Index increasing by 0.42%, and the Hang Seng Technology Index up by 0.13% [1] Group 2 - Since 2026, 143 companies have completed IPO applications, with 120 being first-time submissions. As of February 16, there are still 401 new stock applications pending in the Hong Kong market, including 4 companies that have passed the hearing [3] - Deloitte China predicts that the Hong Kong IPO market in 2026 may surpass last year, with approximately 160 new stocks expected to raise no less than 300 billion HKD [3] - The distribution of companies waiting for IPO includes 81 in the software services sector, 71 in pharmaceuticals and biotechnology, 51 in hardware equipment, and 26 in semiconductors [3] - Recently listed technology companies have attracted significant interest from international long-term investors, with a notable focus on AI, semiconductors, embodied robotics, and biomedicine [3] Group 3 - Chinese securities firms are accelerating their investments in Hong Kong, with Dongwu Securities approved for a capital increase of 2 billion HKD for its Hong Kong subsidiary on February 13 [4] - Huazhang Securities and Northeast Securities have also received approval for capital increases of 500 million HKD each for their Hong Kong subsidiaries [4] - Since the beginning of 2026, Guangfa Securities and Huatai Securities have completed H-share refinancing of 6.1 billion HKD and 10 billion HKD, respectively, aimed at strengthening their overseas business [4] - In December 2025, China Merchants Securities announced a capital increase of up to 9 billion HKD for its wholly-owned subsidiary, with the first phase targeting a capital increase of no more than 4 billion HKD for its Hong Kong subsidiary [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the expected results of their Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in fracture rates, contrary to the positive statements made by the defendants [6]. - The misleading statements allegedly led to investors purchasing shares at inflated prices, resulting in damages when the true information became public [6].

Core Insights - Novo Nordisk is focusing on regaining market share in the GLP-1 space, where it has faced competition from Eli Lilly [1][8] - The company's future growth will depend on the success of its next-generation therapies, particularly CagriSema, as current products are expected to see declining sales [2][6] Product Development - CagriSema is a dual agonist that mimics GLP-1 and amylin, showing promising results in clinical trials [4] - In a phase 3 weight-loss trial, CagriSema achieved a mean weight reduction of 22.7% after 68 weeks, outperforming Wegovy, which had a reduction of 16.1% [4] - Another late-stage study showed CagriSema led to a 1.91% reduction in blood sugar and a 14.2% weight loss in type 2 diabetes patients, surpassing Ozempic's performance [5] Regulatory and Manufacturing Challenges - Novo Nordisk has submitted regulatory applications for CagriSema as a weight loss treatment and plans to seek approval for diabetes treatment after completing additional studies [6] - CagriSema's manufacturing will be more complex and costly compared to semaglutide, which has faced supply constraints [7] Competitive Landscape - Eli Lilly's retatrutide has shown a mean weight loss of up to 28.7%, indicating that Novo Nordisk still faces significant competition [7] - Despite challenges, CagriSema's advantages over Wegovy and Ozempic may enhance Novo Nordisk's market position as the company expands its manufacturing capacity [8] Revenue Potential - Wegovy has received label expansions for treating metabolic dysfunction-associated steatohepatitis (MASH), which could positively impact sales [9] - New approvals and label expansions may help Novo Nordisk's revenue trajectory improve [9]